title: Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.
authors.affiliation: Division of Medicine, University of Texas, M.D. Anderson Cancer Center, USA.
authors.forename: A B
authors.initials: AB
authors.lastname: Deisseroth
authors.forename: F
authors.initials: F
authors.lastname: Holmes
authors.forename: G
authors.initials: G
authors.lastname: Hortobagyi
authors.forename: R
authors.initials: R
authors.lastname: Champlin
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics* / Q000378:metabolism; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000517:prevention & control*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D018076:DNA, Complementary / Q000008:administration & dosage / Q000235:genetics; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000235:genetics; D003673:Defective Viruses / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004992:Ethics, Medical; D005240:Feasibility Studies; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology / Q000627:therapeutic use; D015850:Interleukin-6 / Q000494:pharmacology / Q000627:therapeutic use; D015080:Mesna / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D010865:Pilot Projects; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D012190:Retroviridae / Q000235:genetics*; D012449:Safety; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018076:DNA, Complementary; D004274:DNA, Recombinant; D007377:Interleukin-3; D015850:Interleukin-6; D011993:Recombinant Fusion Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D013852:Thiotepa; D015080:Mesna; D017239:Paclitaxel; D002330:Carmustine